185 related articles for article (PubMed ID: 26819001)
21. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive Mutational and Phenotypic Characterization of New Metastatic Cutaneous Squamous Cell Carcinoma Cell Lines Reveal Novel Drug Susceptibilities.
Perry J; Ashford B; Thind AS; Gauthier ME; Minaei E; Major G; Iyer NG; Gupta R; Clark J; Ranson M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333825
[TBL] [Abstract][Full Text] [Related]
23. Dual blocking of PI3K and mTOR signaling by DHW-221, a novel benzimidazole derivative, exerts antitumor activity in human non-small cell lung cancer.
Qin X; Liu M; Wu Y; Wang S; Lian S; Jia H; Wu Q; Ding H; Zhao Q
Clin Transl Med; 2021 Sep; 11(9):e514. PubMed ID: 34586727
[No Abstract] [Full Text] [Related]
24. Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy.
Tang H; Dilimulati D; Yang Z; Zhou K; Chen X; Sun R; Wang N; Liang Z; Bian S; Zhao J; Song P; Zheng S; Wang H; Xie H
EBioMedicine; 2024 May; 103():105099. PubMed ID: 38604089
[TBL] [Abstract][Full Text] [Related]
25. Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C; Lupia A; Stathis A; Bertoni F
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033478
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 2-Methyl-2-(4-(2-methyl-8-(1
Yang J; Liu Y; Lan S; Yu S; Ma X; Luo D; Shan H; Zhong X; Yan G; Li R
J Med Chem; 2022 Oct; 65(19):12781-12801. PubMed ID: 36191148
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
Sun Q; Chu Y; Zhang N; Chen R; Wang L; Wu J; Dong Y; Li H; Wang L; Tang L; Zhan C; Zhang JQ
J Med Chem; 2024 May; 67(9):7330-7358. PubMed ID: 38661655
[TBL] [Abstract][Full Text] [Related]
28. Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/mTOR/c-Myc signaling.
Shin N; Lee HJ; Sim DY; Im E; Park JE; Park WY; Cho AR; Shim BS; Kim SH
Phytother Res; 2021 Jul; 35(7):3812-3820. PubMed ID: 33856720
[TBL] [Abstract][Full Text] [Related]
29. Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-
Zhou S; Ma Y; Xu R; Tang X
J Biomed Nanotechnol; 2022 Mar; 18(3):693-704. PubMed ID: 35715918
[TBL] [Abstract][Full Text] [Related]
30. Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.
Hu J; Fu S; Zhan Z; Zhang J
Eur J Med Chem; 2024 Feb; 265():116109. PubMed ID: 38183777
[TBL] [Abstract][Full Text] [Related]
31. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
32. Covalent conjugation of AZD8055 with unsaturated fatty acids for the development of mTOR nanoblockers: increasing the therapeutic efficacy of hepatocellular carcinoma treatment.
Chau WK; Lee TKW
EBioMedicine; 2024 May; 103():105113. PubMed ID: 38583261
[No Abstract] [Full Text] [Related]
33. Protein kinases as targets for developing anticancer agents from marine organisms.
Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451
[TBL] [Abstract][Full Text] [Related]
34. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma.
Narayanankutty A
Curr Mol Pharmacol; 2021; 14(5):760-769. PubMed ID: 33494690
[TBL] [Abstract][Full Text] [Related]
35. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Clinical Candidate NTQ1062 as a Potent and Bioavailable Akt Inhibitor for the Treatment of Human Tumors.
Ma C; Wu J; Wang L; Ji X; Wu Y; Miao L; Chen D; Zhang L; Wu Y; Feng H; Tang Y; Zhou Q; Pei J; Yang X; Xu D; You Q; Xie Y
J Med Chem; 2022 Jun; 65(12):8144-8168. PubMed ID: 35679512
[TBL] [Abstract][Full Text] [Related]
38. Comment on: Alnustone inhibits the growth of hepatocellular carcinoma via reactive oxygen species-mediated PI3K/Akt/mTOR/p70S6K axis.
Li Z
Phytother Res; 2023 Jun; 37(6):2215-2216. PubMed ID: 36560899
[No Abstract] [Full Text] [Related]
39. Osthole inhibits GSK-3β/AMPK/mTOR pathway-controlled glycolysis and increases radiosensitivity of subcutaneous transplanted hepatocellular carcinoma in nude mice.
Huang H; Xue J; Xie ML; Xie T
Strahlenther Onkol; 2024 May; 200(5):444-452. PubMed ID: 37963994
[TBL] [Abstract][Full Text] [Related]
40. Overview of Research into mTOR Inhibitors.
Mao B; Zhang Q; Ma L; Zhao DS; Zhao P; Yan P
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
